iQue®3 High-Throughput Screening Cytometry Platform

From regenerative medicine to cancer immunotherapy, the promise of cell therapies continues to expand. However, there are many challenges on the path from research to clinical application – particularly amongst analysis. One of the primary frustrations for researchers today is the complexity of advanced cell models, coupled with the need for efficient and scalable workflows that they can use to screen, characterize and monitor therapeutic cells.

This application guide highlights the use of High-Throughput Screening (HTS) by Cytometry to combat these challenges, particularly for mesenchymal stem cell (MSC), induced pluripotent stem cells (iPSC) and CAR-T studies.

Key topics explored:

• Mesenchymal stem cell identity and differentiation
• Optimizing advanced cell models
• Characterization and optimization of iPSCs
• Phenotypic and functional characterization of CAR-T cells
• Characterization of T cell activation

In this application note, Sartorius addresses challenges in B cell workflows and highlights the drawbacks of traditional hybridoma methods, such as being time-consuming, costly, and inefficient. Sartorius proposes solutions to improve efficiency and performance by characterizing B cells earlier in the hybridoma development workflow. This approach aims to enhance the robustness of B cells, minimizing potential pitfalls in the development of therapeutic antibodies.

Monoclonal antibodies (mAbs) can be used to treat symptoms of inflammatory disease, with their success largely due to their high specificity and affinity for the target antigen. Evaluation of mAb target binding is a critical part of the antibody development process and robust, high-throughout techniques are needed to facilitate rapid screening of antibody libraries. In this application note, Sartorius presents two simple assays that utilize the iQue® Advanced Flow Cytometry Platform and validated reagents to measure the binding of unlabeled therapeutic mAbs to specific targets on live cells.

Antibody based biotherapeutics have revolutionized the development of novel treatments, particularly in cancer. Antibody characterization is an essential step in the antibody discovery and screening workflow, contributing to the understanding of the components and functions of an antibody to move toward quality therapeutic development.

Flow cytometry is an incredibly useful technology used in antibody discovery and characterization. Specifically, high-throughput flow cytometry can provide required information in timescales appropriate for efficient antibody evaluation.

This eBook will highlight some key applications for high-throughput flow cytometry in the profiling of antibodies for therapeutic benefit. In particular, the methods shown will demonstrate the function and benefits of the iQue® advanced flow cytometry platform.

Topics covered include utilizing high-throughput flow cytometry for:

• Accelerating antibody screening and characterization
  
• High throughput, multi-parametric analysis
• Fast and full-scale multipass membrane antibody optimization
• Visualization and quantification of phagocytosis
• Evaluating NK cell killing

The generation of biologic-producing cell lines comprises numerous time-consuming, expensive, and often technically challenging steps.

In this new eBook, we examine these challenges in greater detail and explore a range of intelligent analytical solutions that can be incorporated into cell line development workflows to eliminate bottlenecks in clone selection, fast-track development timelines, optimize CQAs, and reduce costs.

Download your free copy today to learn more about:

• Critical steps in cell line development
• Areas to improve efficiency
• Overcoming bottlenecks through streamlined clone selection
• Accelerating process optimization with integrated analysis tools
  

Accounting for at least 15% of all human pathogens, emerging infectious diseases (EID) pose a significant burden on public health. Vaccination represents one of the most successful prophylactic tools for disease prevention and control, however, the development process is typically lengthy and expensive. While there has been a rapid development of multiple safe and highly effective vaccines in response to the current COVID-19 pandemic, there are still many challenges to overcome. This application note will explore the common challenges of vaccine development and the solutions available to overcome them.

Antibody-based therapeutics represent an important advancement in the progress of infectious disease therapy and cancer treatment options.

The discovery and development of monoclonal antibodies (mAbs) has led to an improved understanding of their therapeutic potential against emerging infectious diseases including COVID-19 and offers one of the most successful therapeutic strategies for cancer in recent years.

In this third edition eBook, we look at some of the successful discovery and development methods for next-generation monoclonal antibody-based therapeutics and vaccines.

In this scientific poster, Sartorius introduces a novel multiplexed assay that simultaneously measures target cell killing, expression of NK cell activation markers, and quantitation of secreted effector proteins and cytokines in a single well of a microtiter plate using a mixed cells and beads assay format and the iQue® platform.

Flow cytometry assays offer significant benefits for studying the hallmarks of apoptosis—with the ability to quantify multiple cellular parameters at once.

In this application note, Sartorius illustrate how the iQue® and iQue® Human 4-Plex Apoptosis Kit can be used to measure apoptosis in a simple, mix and read assay format.

Many fluorescence based methods are available to assess internalization; however, performing these assays can prove challenging due to complicated workflows, large sample sizes and the low throughput of analytical methods such as traditional flow cytometry or confocal microscopy.

In this poster, Sartorius describe a high-throughput, multiplex, no-wash assay that measures antibody internalization, specificity, and cell health from a single 30 uL assay volume in 96- and 384- well formats, with the iQue® platform.

Immune checkpoints are molecules that signal and control the synapse between T cells and antigen presenting cells (APCs). Checkpoint inhibitor therapies aim to target and inhibit the signals that ‘switch off’ T cells, leading to upregulation of T cell activation and tumor cell killing.

The mixed lymphocyte reaction (MLR) mimics the T cell and APC synapse by co-culturing immune cells from two individuals. Consequently, MLR is used as a model, to discover the effects of checkpoint inhibitor drugs in vitro, furthering biological research applications and drug discovery processes.

Join this webinar to find out about:

• The use of the iQue® MLR assay to generate pharmacological outputs for checkpoint inhibitor induced T cell activation
• The impact of checkpoint inhibitor therapeutics on inflammatory cytokine release
• How the iQue® Advanced Flow Cytometry Platform and associated reagent kits can be used to quantify T cell response in MLR

Speaker name: Kirsty McBain, Associate Scientist, iQue® Applications Group, Sartorius

Professional bio Kirsty McBain is an Associate Scientist in the iQue® Applications Group, part of the European based BioAnalytics at Sartorius, where she is involved in the research and development of novel applications.

Kirsty’s efforts are focused on the iQue® advanced flow cytometry platform, supporting a number of the immuno-oncology campaigns.

In recent years, there have been advancements in von Willebrand disease (vWD) testing as well as updates in the diagnosis and management of vWD. Paradigm shifts in vWD testing in the context of new guidelines will likely lead to improvements in vWD diagnosis. In this SelectScience webinar, Dr. Edward Wong will explore these current diagnostic approaches and the advantages of new testing strategies.

Key learning objectives

• Demonstrate the current biological function of von Willebrand factor and how it affects testing strategies in the diagnosis of vWD
• Describe potential new testing strategies in the diagnosis of vWD
• Explain the new changes in the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) 2021 guidelines on the diagnosis of vWD

Who should attend?

• Clinicians (especially Adult and Pediatric Hematologists)
• Clinical Lab Scientists
• Lab Managers and Healthcare Scientists

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Accreditation statement
SelectScience is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. Attendees of this one-hour webinar are also entitled to 1.0 ACCENT Continuing Education Credits from the AACC. This activity was planned in accordance with ACCENT® Standards and Policies. Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email education@aacc.org.

Commercialization of a biologic is a lengthy and expensive process. Successful cell line development (CLD) is heavily dependent upon balancing time and resources with acquiring high-quality data for informed decisions. Each stage of the CLD workflow has challenges and there is a real need for advanced strategies and intelligent use of innovative solutions.

The CellCelector, iQue®, Octet®, and Ambr® 15 CC platforms are perfectly designed to seamlessly work together to streamline the early CLD workflow, enabling data-driven decisions and reducing risk during later stages of biologic development. In this webinar, Dr. Fern Slingsby, Ambr Product Specialist at Sartorius and Dr. Daryl Cole, Applications Scientist at Sartorius, will explain how integration of these platforms can be achieved, and where they best fit into the cell line development workflow.

Key learning objectives

• Learn about the early CLD workflow and the bottlenecks associated with the various stages
• Discover instruments which are suited to high-throughput demands and where they fit into the CLD workflow
• Establish a strategy for a simplified approach to cell line development

Who should attend?

• Analytical scientists and researchers involved in early drug discovery and cell line development
• Bioprocessing engineers and scientists
• Process development engineers and scientists
• Lab managers

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Watch this presentation by Allan Schell, David Apiyo, and Victoria Yatsula, titled: Strategies for simplifying viral vaccine and biotherapeutic discovery. This talk was presented at the SelectScience® Virtual Microbiology and Infectious Disease Summit 2022.

In this video, Dr. Komal Kumar Javarappa, postdoctoral research at University of Helsinki, discusses his work finding new target mechanisms for treating malignant cancers such as multiple myeloma and leukemia. Javarappa explains how the Intellicyt iQue®3 has helped advance his research by enabling him to observe cellular responses to a variety of potential cancer therapeutics.

In this video, Sartorius presents the Intellicyt iQue3, a comprehensive solution for the multiplexed analysis of cells and beads, designed to rapidly generate results not just data. In addition to rapid setup and analysis, this advanced flow cytometry platform promises fast sample acquisition and a newly integrated Enhanced Rinse Station. Whether your destination is identifying a new drug candidate, screening for specific antibody clones, characterizing T cells, or developing the latest immunotherapy, the iQue3 is designed to get the answers to your research questions fast.

In this video, Fiona Coats, head of life science research marketing at Sartorius, outlines the latest line of the high-throughput flow cytometry platforms, as launched at this year's CYTO conference. Here, she explains how the new Intellicyt iQue3 platform is an end-to-end solution designed for speed and ease of use, from set-up to analysis.

Acquire and achieve high-content analysis of multiplexed assays with the Intellicyt® iQue Screener PLUS from Sartorius, and save time, resources and costs across your antibody discovery workflows.

This interview was filmed as part of our coverage of AACR 2019 - see other video highlights here >>

Steve Rees, Vice President of Discovery Biology, AstraZeneca, describes how the Intellicyt iQue Screener has accelerated his research in drug discovery, enabling high-throughput screening and aiding in subsequent lead optimization.

Comprehensive digital guide to high-throughput screening (HTS) by cytometry, featuring assays, application data, and more

A comprehensive and interactive digital guide to advanced flow cytometry with assays, applications, and other resources

Explore the latest application eBooks with top tips on biopharmaceutical characterization and high-content screening

Explore cutting-edge technologies, free downloads, and expert insight to support your research

Explore expert webinars, free downloads, latest methods, and much more to help support biopharmaceutical research

Dr. Komal Kumar Javarappa shares insights from the multidisciplinary forefront of immuno-oncology, where translational biologists race against time to optimize new cancer therapies

Exclusive interviews, free downloads, the latest methods and much more to help support your immuno-oncology research

Discover the importance of high-throughput and robust methodologies for finding ‘needle-in-the-haystack’ therapeutic antibodies

Watch this on-demand webinar to gain insight on how advanced flow cytometry and live-cell analysis can facilitate faster drug development